Publications
Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
The authors use a loss-of-function screens and identified Prmt1, arginine methyltransferase as an essential oncogene and a regulator of translation. Therapeutic agents targeting Prmt1 and translation-associated pathways are potential treatment options for cancer.
Analysis of OncoPPi connectivity (protein-protein interaction network of cancer-associated genes) identified MAP kinase kinase 3 was (MKK3) as one of the major hub proteins in the network. MMK3 regulates cellular growth through phosphorylation of p38 and its activation of MYC through PPI.
Scientists performed a multiplatform-based survey of the PI3K/AKT/mTOR pathway on over 10,000 human cancers across 32 types and identified some rare PIK3CA and PIK3R1 mutations along with known molecular events.
CTD2 scientists at UT Southwestern identify human KRAS and loss of LKB1 lung tumors share metabolic signatures of perturbed nitrogen handling. This genotype imposes a metabolic vulnerability related to a dependence on pyrimidine metabolism in an aggressive subset of NSCLC.
CTD2 investigators at DFCI identified genes required for the survival of cancer cells in the presence of PI3K inhibition using genome-scale shRNA-based apoptosis screens.
CTD2 researchers report improved interpretability of the EDDY-CTRP results by using STITCH (protein) and STRING (drug)-interaction databases to generate evidence networks of drug-mediator pairs. These evidence networks will provide insights to drug sensitivity.
Investigators examined whether circulating miRNAs can be used as prognostic biomarkers in osteosarcoma patients. miR-21, miR-221, and miR-106a were found to be expressed significantly higher in cancer samples and were correlated with outcome.